(29 days)
Not Found
No
The summary describes a physical medical device (stent and delivery system) and does not mention any software, algorithms, or data processing that would indicate the use of AI or ML. The performance studies rely on non-clinical testing, not algorithmic performance metrics.
Yes
The device is intended for the "palliation of malignant neoplasms in the biliary tree," which is a therapeutic purpose to alleviate symptoms or improve quality of life.
No
Explanation: The device is a stent system intended for palliation of malignant neoplasms, not for diagnosis.
No
The device description explicitly states it is comprised of a delivery system and a self-expanding stent, which are physical hardware components.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- Device Description: The provided description clearly states that the Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System is a device comprised of a delivery system and a self-expanding stent. It is designed to be implanted in the biliary tree.
- Intended Use: The intended use is the "palliation of malignant neoplasms in the biliary tree," which means it's used to alleviate symptoms or improve quality of life by opening up blockages caused by tumors. This is a therapeutic intervention, not a diagnostic test.
The device is a medical device used for treatment, not for analyzing samples to diagnose or monitor a condition.
N/A
Intended Use / Indications for Use
The Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System is intended for use in the palliation of malignant neoplasms in the biliary trec.
The Abbott Vascular Devices Abbott Vascular Devices™ Xceed™ Nitinol Self-Expanding Transhepatic Biliary Stent System is intended for use in the palliation of malignant neoplasms in the biliary tree.
Product codes (comma separated list FDA assigned to the subject device)
78 FGE
Device Description
The Abbott Vascular Devices Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System is comprised of a delivery system and a self-expanding stent. The delivery system is an over the wire (OTW) system designed to deliver the self-expanding stent to the biliary tree.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
biliary tree
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Substantial equivalence was confirmed through non-clinical testing.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System (K032929)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 876.5010 Biliary catheter and accessories.
(a)
Identification. A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.(b)
Classification. Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
KOSO103 ***. 1~
FED 1 A 2005
Special 510(k): Device Modification ('ONFIDENTIAL ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
APPENDIX A. 510(k) SUMMARY
| Sponsor/Submitter: | Abbott Laboratories
Abbott Vascular Devices
400 Saginaw Drive
Redwood City, CA 94063 |
|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Ann E. Leonard
Regulatory Affairs Coordinator
Phone:(650) 474-3477
Fax:(650) 474-3041 |
| Date of Submission: | January 17, 2005 |
| Device Trade Name: | Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System |
| Device Common Name: | Biliary Stent and Delivery System |
| Device Classification: | Class II |
| Regulation Number: | 21 CFR 876.5010 |
| Classification Name: | Biliary Catheter and Accessories |
| Product Code: | 78 FGE |
| Predicate Device: | Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System
(K032929) |
| Intended Use: | The Xceed Nitinol Self-Expanding Transhepatic Biliary Stent
System is intended for use in the palliation of malignant neoplasms
in the biliary trec. |
| Device Description: | The Abbott Vascular Devices Xceed Nitinol Self-Expanding
Transhepatic Biliary Stent System is comprised of a delivery system
and a self-expanding stent. The delivery system is an over the wire
(OTW) system designed to deliver the self-expanding stent to the
biliary tree. |
| Summary of Substantial
Equivalence: | The Xceed Nitinol Self-Expanding Transhepatic Biliary Stent
System is substantially equivalent to the predicate device.
Substantial equivalence was confirmed through non-clinical testing. |
1
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract image of an eagle.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
FEB 1 6 2005
Ann E. Leonard, Ph.D. Regulatory Affairs Coordinator Abbott Vascular Devices 400 Saginaw Drive REDWOOD CITY CA 94063
Re: K050103
Trade/Device Name: Xceed™ Nitinol Self-Expanding Transhepatic Biliary Stent System Regulation Number: 21 CFR §876.5010 Regulation Name: Biliary catheter and accessories Regulatory Class: II Product Code: 78 FGE Dated: January 17, 2005 Received: January 18, 2005
Dear Dr. Lconard:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Thereforc, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:
The safety and effectiveness of this device for use in the vascular system have not been established.
Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use. and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.
2
Page 2 - Dr. Ann Leonard
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.
If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4616. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International, and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Qaritu
Donna-Bea Tillman, Ph.D. Director Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Page 1 of 1
510(k) Number: K050103
Device Name: Abbott Vascular Devices™ Xceed™ Nitinol Self-F.xpanding Transhepatic Biliary Stent System
FDA's Statement of the Indications For Use for device:
The Abbott Vascular Devices Abbott Vascular Devices™ Xceed™ Nitinol Self-Expanding Transhepatic Biliary Stent System is intended for use in the palliation of malignant neoplasms in the biliary tree.
Prescription Use /
(Per 21 CFR 801.109)
()[ર
Over-the-Counter Use --------
Javici burdon
(Division Sign-Off) Division of Reproductive, Abdomin and Radiological Devi
510(k) Number K050102